Ecallantide
- 1 min read
- 4 chapters
Related on Lably
Through Medication, Amino acid and Peptide
Medical uses
Angioedema
On November 27, 2009, ecallantide was approved by the FDA for the treatment of acute attacks of hereditary angioedema for persons over 16 years of age. A single dose requires three separate injections, which are given under the skin.
Ecallantide does not appear to be efficacious for the treatment of angioedema due to ACE inhibitors.
Sign in to keep reading
3 more chapters are free with a Lably account.
Adverse effects
The most common adverse effects are headache, nausea, fatigue and diarrhea. Less common, but observed in more than 5% of patients in clinical trials, are respiratory tract infections, fever, vomiting, itching and upper abdominal pain. Up to 4% of patients showed anaphylaxis, which led to a black box warning in the US.
Interactions
As of 2011, no interaction studies have been conducted.
Mechanism of action
HAE is caused by a mutation of the C1-inhibitor gene. Defective or missing C1-inhibitor permits activation of kallikrein, a protease that is responsible for liberating bradykinin from its precursor kininogen. An excess of bradykinin leads to fluid leakage from blood vessels, causing swelling of tissues typical of HAE.
Ecallantide suppresses this pathogenetic mechanism by selectively and reversibly inhibiting the activity of plasma kallikrein. Ecallantide's inhibitory constant (Ki) for kallikrein is 25 picoMolar, indicating high affinity.